NA SJS TEN Treatment Market - Industry Trends and Forecast to 2030 | Pharmaceutical_LifeSciense Market Research Report

Abstract

Summary

North America SJS/TEN treatment market is expected to reach USD 3,485.81 million by 2030 from USD 1,930.49 million in 2022, growing at a CAGR of 7.8% during the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022 and the forecast period is 2023 to 2030. Market Segmentation: North America SJS/TEN Treatment Market, By Treatment (Medications, Support Care, Hospitalization, Isolation, Ointments, and Others), Diagnosis (Physical Exam, Skin Biopsy, Medical History, Blood Test, Cultures, and Others), Cause (Specific Treatment, Infection, and Others), Route of Administration (Oral, Parenteral, Topical, and Others), Drug Type (Branded and Generic), Therapy Area (Combination Therapy and Monotherapy), Patient Type (Geriatric, Adult, and Pediatric), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Center, Homecare Setting, and Others), Distribution Channel (Retail Pharmacies, Direct Tender, and Others), Country (U.S., Canada, Mexico) - Industry Trends & Forecast to 2030 Overview of North America SJS/TEN Treatment Market Dynamics: Driver • Increasing awareness about the rare disease SJS/TEN Restrain • High cost associated with SJS/TEN treatment Opportunity • Lack of identification for the causative agent in many of the cases Market Players: Some of the key market players operating in the North America SJS/TEN treatment market are listed below: • 3M • Cardinal Health • BD • Smith + Nephew • Novartis AG • Amneal Pharmaceuticals LLC. • Amgen Inc. • Pfizer Inc. • Colgate-Palmolive Company • Merck & Co., Inc. • Mölnlycke Health Care AB. • Xttrium Laboratories • Schülke & Mayr GmbH • Purdue Pharma L.P. • AdvaCare Pharma

1 INTRODUCTION 84
- 1.1 OBJECTIVES OF THE STUDY 84
- 1.2 MARKET DEFINITION 84
- 1.3 OVERVIEW OF THE NORTH AMERICA SJS/TEN TREATMENT MARKET 84
- 1.4 LIMITATIONS 87
- 1.5 MARKETS COVERED 87
2 MARKET SEGMENTATION 92
- 2.1 MARKETS COVERED 92
- 2.2 GEOGRAPHICAL SCOPE 93
- 2.3 YEARS CONSIDERED FOR THE STUDY 94
- 2.4 CURRENCY AND PRICING 94
- 2.5 DBMR TRIPOD DATA VALIDATION MODEL 95
- 2.6 MULTIVARIATE MODELLING 98
- 2.7 TREATMENT LIFELINE CURVE 98
- 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 99
- 2.9 DBMR MARKET POSITION GRID 100
- 2.10 MARKET APPLICATION COVERAGE GRID 101
- 2.11 VENDOR SHARE ANALYSIS 102
- 2.12 SECONDARY SOURCES 103
- 2.13 ASSUMPTIONS 103
3 EXECUTIVE SUMMARY 104
4 PREMIUM INSIGHTS 107
- 4.1 KEY TRENDS 108
- 4.2 COST OF TREATMENT 109
- 4.3 KEY PLAYERS STRATEGIES 110
- 4.4 LONG TERM GROWTH APPROACH 111
5 EPIDEMIOLOGY 112
6 INDUSTRY INSIGHTS 116
- 6.1 PATENT ANALYSIS 116
- 6.2 DEMOGRAPHIC TRENDS 118
- 6.3 PATIENT FLOW DIAGRAM 119
- 6.4 KEY PRICING STRATEGIES 120
- 6.5 KEY PATIENT ENROLLMENT STRATEGIES 120
7 MARKET OVERVIEW 123
- 7.1 DRIVERS 125
  - 7.1.1 INCREASING PREVALENCE AND INCIDENCE OF SJS/TEN 125
  - 7.1.2 ADVANCES IN DRUG DEVELOPMENT FOR SJS/TEN TREATMENT 126
  - 7.1.3 INCREASING AWARENESS ABOUT THE RARE DISEASE SJS/TEN 126
  - 7.1.4 GOVERNMENT INITIATIVES FOR SJS/TEN TREATMENT 127
- 7.2 RESTRAINTS 129
  - 7.2.1 HIGH COST ASSOCIATED WITH THE TREATMENT OF SJS/TEN 129
  - 7.2.2 LIMITED AVAILABILITY OF SPECIALIZED CARE FOR SJS/TEN TREATMENT 129
- 7.3 OPPORTUNITIES 130
  - 7.3.1 DEVELOPING EFFECTIVE AND SAFE TREATMENT FOR SJS/TEN 130
  - 7.3.2 INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES FOR SJS/TEN TREATMENT 131
- 7.4 CHALLENGES 131
  - 7.4.1 STRINGENT GOVERNMENT REGULATIONS FOR APPROVAL OF TREATMENT FOR SJS/TEN 131
  - 7.4.2 LONG TERM COMPLICATIONS AND ADVERSE EFFECTS OF MEDICATIONS USED IN THE SJS/TEN TREATMENT 132
8 NORTH AMERICA SJS/TEN TREATMENT MARKET, BY TREATMENT 133
- 8.1 OVERVIEW 134
- 8.2 MEDICATIONS 137
  - 8.2.1 ANTIHISTAMINES 138
    - 8.2.1.1 HYDROXYZINE 138
    - 8.2.1.2 FEXOFENADINE 138
  - 8.2.2 CORTICOSTEROID 139
    - 8.2.2.1 DEXAMETHASONE 139
    - 8.2.2.2 PREDNISOLONE 139
    - 8.2.2.3 METHYLPREDNISOLONE 139
    - 8.2.2.4 HYDROCORTISONE 139
    - 8.2.2.5 OTHERS 139
  - 8.2.3 ANTIBIOTICS 139
    - 8.2.3.1 NAFCILLIN 140
    - 8.2.3.2 GENTAMICIN 140
    - 8.2.3.3 OTHERS 140
  - 8.2.4 ANALGESICS 140
    - 8.2.4.1 MORPHINE 140
    - 8.2.4.2 FENTANYL CITRATE 141
    - 8.2.4.3 OTHERS 141
  - 8.2.5 ANTICOAGULANTS 141
  - 8.2.6 ANTISEPTICS 141
    - 8.2.6.1 CHLORHEXIDINE GLUCONATE 141
      - 8.2.6.1.1 PERIOGARD 142
      - 8.2.6.1.2 PERIDEX 142
      - 8.2.6.1.3 AVAGARD 142
      - 8.2.6.1.4 HIBICLENS 142
      - 8.2.6.1.5 OTHERS 142
    - 8.2.6.2 OCTENISEPT 142
    - 8.2.6.3 POLYHEXANIDE SOLUTIONS 142
    - 8.2.6.4 OTHERS 143
  - 8.2.7 INTRAVENOUS IMMUNOGLOBULIN 143
  - 8.2.8 CYCLOSPORINE 143
    - 8.2.8.1 NEORAL 143
    - 8.2.8.2 SANDIMMUNE 143
    - 8.2.8.3 OTHERS 143
  - 8.2.9 TUMOR NECROSIS FACTOR-ALPHA (TNF-Α)-BLOCKING AGENT (ETANERCEPT) 143
  - 8.2.10 OTHER TREATMENT 144
    - 8.2.10.1 CYCLOPHOSPHAMIDE 144
    - 8.2.10.2 N-ACETYLCYSTEINE 144
    - 8.2.10.3 MONOCLONAL ANTIBODIES 144
    - 8.2.10.4 THALIDOMIDE 144
- 8.3 SUPPORT CARE 144
  - 8.3.1 INTRAVENOUS (IV) FLUID AND ELECTROLYTES 145
  - 8.3.2 PAIN MANAGEMENT 146
    - 8.3.2.1 LIDOCAINE 146
    - 8.3.2.2 OTHERS 146
  - 8.3.3 NUTRITION SUPPORT 146
  - 8.3.4 ORAL CARE 146
  - 8.3.5 PLASMAPHERESIS 146
  - 8.3.6 BANDAGES 146
    - 8.3.6.1 BIOLOGICAL DRESSING 147
      - 8.3.6.1.1 ALLOGRAFT 147
      - 8.3.6.1.2 XENOGRAFT 147
      - 8.3.6.1.3 HOMOGRAFT 147
      - 8.3.6.1.4 OTHERS 147
    - 8.3.6.2 BIOSYNTHETIC DRESSING 148
    - 8.3.6.3 SILVER IMPREGNATED DRESSING 148
- 8.4 HOSPITALIZATION 148
- 8.5 ISOLATION 149
- 8.6 OINTMENTS 149
  - 8.6.1 BENZOCAINE 150
  - 8.6.2 AMERICAINE 150
  - 8.6.3 ANBESOL 150
  - 8.6.4 CHIGGEREX PLUS 150
  - 8.6.5 OTHERS 151
- 8.7 OTHERS 151
9 NORTH AMERICA SJS/TEN TREATMENT MARKET, BY DIAGNOSIS 152
- 9.1 OVERVIEW 153
- 9.2 PHYSICAL EXAM 156
- 9.3 SKIN BIOPSY 156
- 9.4 MEDICAL HISTORY 157
- 9.5 BLOOD TEST 158
  - 9.5.1 COMPLETE BLOOD COUNT 159
  - 9.5.2 ERYTHROCYTE SEDIMENTATION RATE 159
  - 9.5.3 COAGULATION STUDIES 159
  - 9.5.4 UREA AND ELECTROLYTES 160
  - 9.5.5 LIVER FUNCTION TEST 160
- 9.6 CULTURES 160
- 9.7 OTHERS 161
10 NORTH AMERICA SJS/TEN TREATMENT MARKET, BY CAUSE 162
- 10.1 OVERVIEW 163
- 10.2 SPECIFIC TREATMENT 166
- 10.3 INFECTION 166
- 10.4 OTHERS 167
11 NORTH AMERICA SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 168
- 11.1 OVERVIEW 169
- 11.2 ORAL 172
- 11.3 PARENTERAL 172
  - 11.3.1 INTRAVENOUS 173
  - 11.3.2 SUBCUTANEOUS 173
  - 11.3.3 OTHERS 173
- 11.4 TOPICAL 173
  - 11.4.1 OINTMENTS 174
  - 11.4.2 SOLUTION 174
  - 11.4.3 CREAMS 175
  - 11.4.4 OTHERS 175
- 11.5 OTHERS 175
12 NORTH AMERICA SJS/TEN TREATMENT MARKET, BY DRUG TYPE 176
- 12.1 OVERVIEW 177
- 12.2 BRANDED 180
  - 12.2.1 NEORAL 181
  - 12.2.2 SANDIMMUNE 181
  - 12.2.3 VISTARIL 181
  - 12.2.4 DURAMORPH 181
  - 12.2.5 FENTORA 181
  - 12.2.6 ENBREL 181
  - 12.2.7 OTHERS 181
- 12.3 GENERIC 181
13 NORTH AMERICA SJS/TEN TREATMENT MARKET, BY THERAPY TYPE 183
- 13.1 OVERVIEW 184
- 13.2 COMBINATION THERAPY 187
- 13.3 MONOTHERAPY 187
14 NORTH AMERICA SJS/TEN TREATMENT MARKET, BY PATIENT TYPE 189
- 14.1 OVERVIEW 190
- 14.2 GERIATRIC 193
  - 14.2.1 FEMALE 194
  - 14.2.2 MALE 194
- 14.3 ADULT 194
  - 14.3.1 FEMALE 195
  - 14.3.2 MALE 195
- 14.4 PEDIATRIC 195
15 NORTH AMERICA SJS/TEN TREATMENT MARKET, BY END USER 197
- 15.1 OVERVIEW 198
- 15.2 HOSPITALS 201
- 15.3 SPECIALTY CLINICS 201
- 15.4 AMBULATORY SURGICAL CENTER 202
- 15.5 HOMECARE SETTING 203
- 15.6 OTHERS 203
16 NORTH AMERICA SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL 205
- 16.1 OVERVIEW 206
- 16.2 RETAIL PHARMACIES 209
  - 16.2.1 HOSPITAL ASSOCIATED PHARMACIES 210
  - 16.2.2 DRUG STORE 210
  - 16.2.3 ONLINE PHARMACIES 210
- 16.3 DIRECT TENDERS 210
- 16.4 OTHERS 211
17 NORTH AMERICA SJS/TEN TREATMENT MARKET, BY REGION 212
- 17.1 NORTH AMERICA 213
  - 17.1.1 U.S 227
  - 17.1.2 CANADA 235
  - 17.1.3 MEXICO 244
18 NORTH AMERICA SJS/TEN TREATMENT MARKET, COMPANY LANDSCAPE 253
- 18.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 253
19 SWOT ANALYSIS 254
20 COMPANY PROFILE 255
- 20.1 PFIZER INC 255
  - 20.1.1 COMPANY SNAPSHOT 255
  - 20.1.2 REVENUE ANALYSIS 255
  - 20.1.3 COMPANY SHARE ANALYSIS 256
  - 20.1.4 PRODUCT PORTFOLIO 256
  - 20.1.5 RECENT DEVELOPMENT 256
- 20.2 NOVARTIS AG 257
  - 20.2.1 COMPANY SNAPSHOT 257
  - 20.2.2 REVENUE ANALYSIS 257
  - 20.2.3 COMPANY SHARE ANALYSIS 258
  - 20.2.4 PRODUCT PORTFOLIO 258
  - 20.2.5 RECENT DEVELOPMENT 258
- 20.3 MERCK & CO., INC 259
  - 20.3.1 COMPANY SNAPSHOT 259
  - 20.3.2 REVENUE ANALYSIS 259
  - 20.3.3 COMPANY SHARE ANALYSIS 260
  - 20.3.4 PRODUCT PORTFOLIO 260
  - 20.3.5 RECENT DEVELOPMENT 260
- 20.4 AMNEAL PHARMACEUTICAL LLC 261
  - 20.4.1 COMPANY SNAPSHOT 261
  - 20.4.2 REVENUE ANALYSIS 261
  - 20.4.3 COMPANY SHARE ANALYSIS 262
  - 20.4.4 PRODUCT PORTFOLIO 262
  - 20.4.5 RECENT DEVELOPMENT 262
- 20.5 AMGEN INC 263
  - 20.5.1 COMPANY SNAPSHOT 263
  - 20.5.2 REVENUE ANALYSIS 263
  - 20.5.3 PRODUCT PORTFOLIO 264
  - 20.5.4 RECENT DEVELOPMENT 264
- 20.6 ADVACARE PHARMA 265
  - 20.6.1 COMPANY SNAPSHOT 265
  - 20.6.2 PRODUCT PORTFOLIO 265
  - 20.6.3 RECENT DEVELOPMENT 265
- 20.7 BD 266
  - 20.7.1 COMPANY SNAPSHOT 266
  - 20.7.2 REVENUE ANALYSIS 266
  - 20.7.3 PRODUCT PORTFOLIO 267
  - 20.7.4 RECENT DEVELOPMENT 267
- 20.8 CARDINAL HEALTH 268
  - 20.8.1 COMPANY SNAPSHOT 268
  - 20.8.2 REVENUE ANALYSIS 268
  - 20.8.3 PRODUCT PORTFOLIO 269
  - 20.8.4 RECENT DEVELOPMENT 269
- 20.9 COLGATE-PALMOLIVE COMPANY 270
  - 20.9.1 COMPANY SNAPSHOT 270
  - 20.9.2 REVENUE ANALYSIS 270
  - 20.9.3 PRODUCT PORTFOLIO 271
  - 20.9.4 RECENT DEVELOPMENT 271
- 20.10 EUGIA (SUBSIDIARY OF AUROBINDO PHARMA) 272
  - 20.10.1 COMPANY SNAPSHOT 272
  - 20.10.2 REVENUE ANALYSIS 272
  - 20.10.3 PRODUCT PORTFOLIO 273
  - 20.10.4 RECENT DEVELOPMENT 273
- 20.11 ICPA HEALTH PRODUCTS LTD 274
  - 20.11.1 COMPANY SNAPSHOT 274
  - 20.11.2 PRODUCT PORTFOLIO 274
  - 20.11.3 RECENT DEVELOPMENT 274
- 20.12 3M 275
  - 20.12.1 COMPANY SNAPSHOT 275
  - 20.12.2 REVENUE ANALYSIS 275
  - 20.12.3 PRODUCT PORTFOLIO 276
  - 20.12.4 RECENT DEVELOPMENT 276
- 20.13 MOLNLYCKE HEALTH CARE AB 277
  - 20.13.1 COMPANY SNAPSHOT 277
  - 20.13.2 PRODUCT PORTFOLIO 277
  - 20.13.3 RECENT DEVELOPMENT 277
- 20.14 PURDUE PHARMA L.P 278
  - 20.14.1 COMPANY SNAPSHOT 278
  - 20.14.2 PRODUCT PORTFOLIO 278
  - 20.14.3 RECENT DEVELOPMENT 278
- 20.15 SCHULKE & MAYR GMBH 279
  - 20.15.1 COMPANY SNAPSHOT 279
  - 20.15.2 PRODUCT PORTFOLIO 279
  - 20.15.3 RECENT DEVELOPMENT 279
- 20.16 SMITH + NEPHEW 280
  - 20.16.1 COMPANY SNAPSHOT 280
  - 20.16.2 REVENUE ANALYSIS 280
  - 20.16.3 PRODUCT PORTFOLIO 281
  - 20.16.4 RECENT DEVELOPMENT 281
- 20.17 XTTRIUM LABORATORIES 282
  - 20.17.1 COMPANY SNAPSHOT 282
  - 20.17.2 PRODUCT PORTFOLIO 282
  - 20.17.3 RECENT DEVELOPMENT 282
21 QUESTIONNAIRE 283
22 RELATED REPORTS 287

NA SJS TEN Treatment Market - Industry Trends and Forecast to 2030 ‐ Pharmaceutical_LifeSciense Market

NA SJS TEN Treatment Market - Industry Trends and Forecast to 2030 ‐ Pharmaceutical_LifeSciense Market

Abstract

Summary

Table of Contents

1 INTRODUCTION 84

1.1 OBJECTIVES OF THE STUDY 84

1.2 MARKET DEFINITION 84

1.3 OVERVIEW OF THE NORTH AMERICA SJS/TEN TREATMENT MARKET 84

1.4 LIMITATIONS 87

1.5 MARKETS COVERED 87

2 MARKET SEGMENTATION 92

2.1 MARKETS COVERED 92

2.2 GEOGRAPHICAL SCOPE 93

2.3 YEARS CONSIDERED FOR THE STUDY 94

2.4 CURRENCY AND PRICING 94

2.5 DBMR TRIPOD DATA VALIDATION MODEL 95

2.6 MULTIVARIATE MODELLING 98

2.7 TREATMENT LIFELINE CURVE 98

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 99

2.9 DBMR MARKET POSITION GRID 100

2.10 MARKET APPLICATION COVERAGE GRID 101

2.11 VENDOR SHARE ANALYSIS 102

2.12 SECONDARY SOURCES 103

2.13 ASSUMPTIONS 103

3 EXECUTIVE SUMMARY 104

4 PREMIUM INSIGHTS 107

4.1 KEY TRENDS 108

4.2 COST OF TREATMENT 109

4.3 KEY PLAYERS STRATEGIES 110

4.4 LONG TERM GROWTH APPROACH 111

5 EPIDEMIOLOGY 112

6 INDUSTRY INSIGHTS 116

6.1 PATENT ANALYSIS 116

6.2 DEMOGRAPHIC TRENDS 118

6.3 PATIENT FLOW DIAGRAM 119

6.4 KEY PRICING STRATEGIES 120

6.5 KEY PATIENT ENROLLMENT STRATEGIES 120

7 MARKET OVERVIEW 123

7.1 DRIVERS 125

7.1.1 INCREASING PREVALENCE AND INCIDENCE OF SJS/TEN 125

7.1.2 ADVANCES IN DRUG DEVELOPMENT FOR SJS/TEN TREATMENT 126

7.1.3 INCREASING AWARENESS ABOUT THE RARE DISEASE SJS/TEN 126

7.1.4 GOVERNMENT INITIATIVES FOR SJS/TEN TREATMENT 127

7.2 RESTRAINTS 129

7.2.1 HIGH COST ASSOCIATED WITH THE TREATMENT OF SJS/TEN 129

7.2.2 LIMITED AVAILABILITY OF SPECIALIZED CARE FOR SJS/TEN TREATMENT 129

7.3 OPPORTUNITIES 130

7.3.1 DEVELOPING EFFECTIVE AND SAFE TREATMENT FOR SJS/TEN 130

7.3.2 INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES FOR SJS/TEN TREATMENT 131

7.4 CHALLENGES 131

7.4.1 STRINGENT GOVERNMENT REGULATIONS FOR APPROVAL OF TREATMENT FOR SJS/TEN 131

7.4.2 LONG TERM COMPLICATIONS AND ADVERSE EFFECTS OF MEDICATIONS USED IN THE SJS/TEN TREATMENT 132

8 NORTH AMERICA SJS/TEN TREATMENT MARKET, BY TREATMENT 133

8.1 OVERVIEW 134

8.2 MEDICATIONS 137

8.2.1 ANTIHISTAMINES 138

8.2.2 CORTICOSTEROID 139

8.2.3 ANTIBIOTICS 139

8.2.4 ANALGESICS 140

8.2.5 ANTICOAGULANTS 141

8.2.6 ANTISEPTICS 141

8.2.7 INTRAVENOUS IMMUNOGLOBULIN 143

8.2.8 CYCLOSPORINE 143

8.2.9 TUMOR NECROSIS FACTOR-ALPHA (TNF-Α)-BLOCKING AGENT (ETANERCEPT) 143

8.2.10 OTHER TREATMENT 144

8.3 SUPPORT CARE 144

8.3.1 INTRAVENOUS (IV) FLUID AND ELECTROLYTES 145

8.3.2 PAIN MANAGEMENT 146

8.3.3 NUTRITION SUPPORT 146

8.3.4 ORAL CARE 146

8.3.5 PLASMAPHERESIS 146

8.3.6 BANDAGES 146

8.4 HOSPITALIZATION 148

8.5 ISOLATION 149

8.6 OINTMENTS 149

8.6.1 BENZOCAINE 150

8.6.2 AMERICAINE 150

8.6.3 ANBESOL 150

8.6.4 CHIGGEREX PLUS 150